Syndax Pharmaceuticals
SNDX | NASDAQ
$9.13
-$0.32 (-3.39%)
At close: Nov 16, 2026, 4:00 PM ET
$9.20
+$0.07 (+0.77%)
After-hours:
Nov 16, 2026, 7:54 PM ET
Syndax Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Michael A. Metzger | Chief Executive Officer & Director |
| Averi Price | Senior VP of Legal & Chief Compliance Officer |
| Keith Alan Goldan | CFO, Treasurer & Principal Accounting Officer |
| Luke J. Albrecht | General Counsel & Corporate Secretary |
| Michael Downes | Co-Founder |
| Nicholas Botwood MBBS | Head of Research & Development and Chief Medical Officer |
| Peter Ordentlich | Co-Founder & Chief Scientific Officer |
| Richard A. Heyman | Co-Founder |
| Ronald Evans | Co-Founder, Advisor and Chair of Scientific Advisory Board |
| Sharon Klahre | Vice President of Investor Relations & Communications |
| Steven Closter | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 8-K | Current Report |
| Jul 09, 2026 | 4 | Filing |
| Jun 12, 2026 | 4 | Filing |
| Jun 10, 2026 | 8-K | Current Report |
| Jun 10, 2026 | 8-K | Current Report |
| Jun 04, 2026 | DEFA14A | Filing |
Syndax Pharmaceuticals
| Country | United States |
| IPO Date | Mar 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 298 |
| CEO | Michael A. Metzger |
Contact Details
730 Third Avenue New York City,
New York 10017 United States
Stock Details
| Ticker Symbol | SNDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001395937 |
| CUSIP Number | 87164F105 |
| ISIN Number | US87164F1057 |
| SIC Code | 2834 |
Recent News
- 14 days ago / seekingalpha.comSyndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript
- 14 days ago / marketbeat.comWhat Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call
- 14 days ago / zacks.comSyndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates
- 14 days ago / globenewswire.comSyndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
- 14 days ago / globenewswire.comSyndax Reports Third Quarter 2026 Financial Results and Provides Business Update
- 18 days ago / globenewswire.comSyndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
- 18 days ago / globenewswire.comSyndax Announces Participation in November Investor Conferences
- 22 days ago / zacks.comSyndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- 22 days ago / globenewswire.comSyndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
- 1 month ago / globenewswire.comSyndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List
Add to Watchlist
Select watchlists to add or remove SNDX